A significant response to sunitinib in a patient with anaplastic thyroid carcinoma
Grande, Enrique (Hospital Universitari Vall d'Hebron)
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron)
Díez, Juan José (Hospital Universitario Ramón y Cajal (Madrid))
Longo, Federico (Hospital Universitario Ramón y Cajal (Madrid))
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid))
Universitat Autònoma de Barcelona

Date:	2013
Abstract:	Anaplastic thyroid cancer (ATC) is a rare disease with an incidence of less than three cases per million of habitants in western countries. ATC accounts for 1-10% of all tumors derived from the thyroid gland. Classic chemotherapy approach based on platinum and anthracyclines regimens have been considered standard for the last decades. Novel multitarget agents have shown promising responses; however, no positive randomized clinical trials are available up to now. To our knowledge, the case we are presenting here is the first reported case showing clinical and visual activity using sunitinib as a salvage treatment in an ATC patient who was not fit to receive systemic chemotherapy treatment.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra, i la creació d'obres derivades, sempre que no sigui amb finalitats comercials i que es distribueixin sota la mateixa llicència que regula l'obra original. Cal que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Anaplastic thyroid cancer ; Angiogenesis ; Sunitinib
Published in:	Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences, Vol. 18 (july 2013) , p. 623-625, ISSN 1735-7136

PMID: 24516498

5 p, 265.2 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles